SEC Form 3 · accession 0002144116-26-000004
ORAGENICS INC · OGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Spencer
Officer — Chief Financial Officer
Period of report
Jul 1, 2026
Accepted (ET)
Jul 7, 2026 · 5:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001174940
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 53 | I | By Spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $0.93 | holding | — | — | — | — | Dec 11, 2035 | Common Stock | 10,000 | — | D |
Explanation of responses
- F1Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One third of the options vest on the first anniversary of the grant date and the remainder of the options subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant.